BeyondSpring publishes corporate deck highlighting plinabulin immune-modulating cancer therapy pipeline

BeyondSpring Inc.

BeyondSpring Inc.

BYSI

0.00
  • BeyondSpring highlighted Phase 3 Dublin-3 data in 2L/3L EGFR wild-type NSCLC: median OS 10.5 months vs 9.4; HR 0.82; p=0.0399.
  • Dublin-3 showed lower grade 4 neutropenia on day 8 across all cycles: 22.3% vs 43.5% for docetaxel alone.
  • Post-hoc non-squamous subgroup: median OS 11.37 months vs 8.81; HR 0.72; p=0.0078.
  • Mechanism-enriched post-PD-1/L1 subgroup: median OS 15.8 months vs 11.7; HR 0.55; p=0.076.
  • Planned Dublin-4 confirmatory Phase 3 in non-squamous NSCLC progressed on PD-1/L1 with PFS at least 3 months.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.